nephron by interference with different transport mechanisms. All but the last two groups have in common a capacity to cause excessive urinary loss of potassium. Many of the edematous states in which abnormal sodium retention is to be attacked are per se often associated with secondary hyperaldosteronism and, if not with hypokalemia, with a greater tendency to lose potassium with diuresis.1 This setting can operate to limit the use of the stronger diuretic agents. Often the concomitant administration of potassium salts is recommended, but this approach may lead to cardiac toxicity or introduce new hazards.2 For these reasons there is a need for agents which could inhibit the renal po-BULL, LARAGH tassium loss so frequently associated with therapy. Spirolactone and triamterene can retard renal potassium excretion and therefore have proven of some value when used in combination with the other more potent agents. But the usefulness of these agents has often been limited by a lack of sufficient potency or by the delay in onset or disappearance of effect.
In this report we present results of preliminary evaluations of a new and apparently more powerful potassium-retaining natriuretic agent, amiloride ( fig. 1 ). The effects of this pyrazinoyl guanidine compound have been studied in normal subjects, in patients with essential hypertension, and in patients with various edematous states. The compound has been evaluated when given alone or in combination with other agents with respect to its influence on sodium, potassium, and water balance, acid-base balance, arterial blood pressure, and the renin-angiotensin-aldosterone system.
Methods
The studies were carried out primarily on the research ward under conditions of controlled electrolyte and metabolism balance. The metabolic ward techniques and analytical methods for blood and urine have been previously described.3 For balance studies the subjects were maintained on a fixed diet of known composition for 4 to *JO and CA had cirrhosis; CT had congestive heart failure. The influence of amiloride on plasma renin activity and aldosterone secretion or excretion was measured in three hypertensive subjects, in two patients with localized lymphedema, and in one normal volunteer (table 3) . Increases in aldosterone output of 0.4 to 13-fold occurred with parallel though often lesser rises in plasma renin activity. Thus the stimulus to increased aldosterone secretion appears to have been mediated in part by the renin-angiotensin system. An additional and complementary direct stimulating effect of Circulation, Volume XXXVI., January 1968 Aldosterone secretion increased markedly in response to amiloride administration. This is in accord with observations in animals of hyperplasia of the adrenal zona glomerulosa following the administration of amiloride, triamterene, or spirolactone (Bagdon, W. J., and Dagle, G. E.: Personal communication). However, there was a lesser increase in plasma renin. Therefore, it could be argued that the hyperaldosteronism was not wholly secondary to the renin-angiotensin system, but also was Circulation, Volume XXXVII, January 1968 largely a direct adrenal response to induced potassium retention. 14 The effects of amiloride have been shown to begin promptly, with peak action in 4 to 8 hours, and to cease within 24 hours. 6 The compound was well tolerated and appeared to have no significant toxicity. A minimal, transient rise of SGOT was noted in 2 patients and slight elevations in BUN were encountered in two previously mildly azotemic subjects. Others have reported slight increases in BUN7 8 and uric acid7' 10; however, the drug does not appear to have the hyperuricemic' 7 or hyperglycemic action characteristic of thiazide diuretics. No deleterious effects have been found on renal clearance studies.6 10 Potassium retention, actually a pharmacological rather than a toxic effect, should be followed closely if the drug is given alone for a prolonged period or if any renal or hepatic insufficiency is present. Similarly, concomitant potassium supplementation should be avoided unless it is carefully monitored.
This experience suggests that perhaps more emphasis should be given to using the socalled mild diuretic in clinical practice.15 Intermittent therapy with agents which are more potent on initial administration frequently leads to violent shifts in electrolytes and water. The subtle but persistent net gain in sodium loss without sacrifice of potassium in an even, sustained way may represent a more desirable therapeutic alternative.
